2020 Q2 Form 10-Q Financial Statement
#000156459020040120 Filed on August 14, 2020
Income Statement
| Concept | 2020 Q2 | 2019 Q2 |
|---|---|---|
| Revenue | $2.938M | $8.645M |
| YoY Change | -66.02% | -28.87% |
| Cost Of Revenue | $1.997M | $5.265M |
| YoY Change | -62.07% | -32.93% |
| Gross Profit | $941.0K | $3.380M |
| YoY Change | -72.16% | -21.58% |
| Gross Profit Margin | 32.03% | 39.1% |
| Selling, General & Admin | $4.230M | $5.783M |
| YoY Change | -26.85% | -24.21% |
| % of Gross Profit | 449.52% | 171.09% |
| Research & Development | $690.0K | $1.124M |
| YoY Change | -38.61% | -17.35% |
| % of Gross Profit | 73.33% | 33.25% |
| Depreciation & Amortization | $310.0K | $270.0K |
| YoY Change | 14.81% | 8.0% |
| % of Gross Profit | 32.94% | 7.99% |
| Operating Expenses | $4.920M | $6.717M |
| YoY Change | -26.75% | -25.2% |
| Operating Profit | -$3.979M | -$3.337M |
| YoY Change | 19.24% | -28.54% |
| Interest Expense | -$625.0K | -$529.0K |
| YoY Change | 18.15% | 140.45% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $665.0K | -$534.0K |
| YoY Change | -224.53% | |
| Pretax Income | -$4.644M | -$3.871M |
| YoY Change | 19.97% | -21.0% |
| Income Tax | $53.00K | $28.00K |
| % Of Pretax Income | ||
| Net Earnings | -$4.697M | -$3.899M |
| YoY Change | 20.47% | -20.59% |
| Net Earnings / Revenue | -159.87% | -45.1% |
| Basic Earnings Per Share | -$0.12 | |
| Diluted Earnings Per Share | -$0.12 | -$172.5K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 37.99M | |
| Diluted Shares Outstanding | 37.99M |
Balance Sheet
| Concept | 2020 Q2 | 2019 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $5.440M | $3.720M |
| YoY Change | 46.24% | 28.28% |
| Cash & Equivalents | $5.749M | $3.720M |
| Short-Term Investments | ||
| Other Short-Term Assets | $1.400M | $1.260M |
| YoY Change | 11.11% | -31.89% |
| Inventory | $11.93M | $12.33M |
| Prepaid Expenses | ||
| Receivables | $4.120M | $9.740M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $22.89M | $27.06M |
| YoY Change | -15.4% | -7.21% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $1.430M | $1.585M |
| YoY Change | -9.78% | -49.84% |
| Goodwill | $2.926M | |
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $510.0K | $793.0K |
| YoY Change | -35.69% | 98.25% |
| Total Long-Term Assets | $4.870M | $5.304M |
| YoY Change | -8.18% | -18.27% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $22.89M | $27.06M |
| Total Long-Term Assets | $4.870M | $5.304M |
| Total Assets | $27.76M | $32.36M |
| YoY Change | -14.22% | -9.22% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.510M | $5.878M |
| YoY Change | -57.3% | -15.18% |
| Accrued Expenses | $2.950M | $4.899M |
| YoY Change | -39.78% | 7.91% |
| Deferred Revenue | $1.486M | $2.513M |
| YoY Change | -40.87% | 13.61% |
| Short-Term Debt | $13.54M | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $21.09M | $13.29M |
| YoY Change | 58.69% | -9.78% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $3.140M | $13.33M |
| YoY Change | -76.44% | 16560.0% |
| Other Long-Term Liabilities | $2.220M | $1.880M |
| YoY Change | 18.09% | 452.94% |
| Total Long-Term Liabilities | $3.140M | $13.33M |
| YoY Change | -76.44% | 3073.33% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $21.09M | $13.29M |
| Total Long-Term Liabilities | $3.140M | $13.33M |
| Total Liabilities | $26.45M | $28.57M |
| YoY Change | -7.43% | 87.22% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$225.5M | |
| YoY Change | ||
| Common Stock | $230.0M | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $1.308M | $3.800M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $27.76M | $32.36M |
| YoY Change | -14.22% | -9.22% |
Cashflow Statement
| Concept | 2020 Q2 | 2019 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$4.697M | -$3.899M |
| YoY Change | 20.47% | -20.59% |
| Depreciation, Depletion And Amortization | $310.0K | $270.0K |
| YoY Change | 14.81% | 8.0% |
| Cash From Operating Activities | -$5.210M | -$1.600M |
| YoY Change | 225.63% | -55.43% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$70.00K | -$120.0K |
| YoY Change | -41.67% | 1100.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | -$70.00K | -$120.0K |
| YoY Change | -41.67% | 1100.0% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 9.130M | 2.470M |
| YoY Change | 269.64% | -230.69% |
| NET CHANGE | ||
| Cash From Operating Activities | -5.210M | -1.600M |
| Cash From Investing Activities | -70.00K | -120.0K |
| Cash From Financing Activities | 9.130M | 2.470M |
| Net Change In Cash | 3.850M | 750.0K |
| YoY Change | 413.33% | -113.66% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$5.210M | -$1.600M |
| Capital Expenditures | -$70.00K | -$120.0K |
| Free Cash Flow | -$5.140M | -$1.480M |
| YoY Change | 247.3% | -58.66% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q2 | us-gaap |
Liabilities
Liabilities
|
26447000 | |
| CY2020Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
3965000 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4903000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1680000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2549000 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
14603000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7702000 | ||
| CY2019Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-5000 | |
| CY2019Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
8645000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
7721000 | ||
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
18971000 | ||
| CY2019Q2 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
5265000 | |
| us-gaap |
Cost Of Revenue
CostOfRevenue
|
5427000 | ||
| us-gaap |
Cost Of Revenue
CostOfRevenue
|
12070000 | ||
| CY2019Q2 | us-gaap |
Gross Profit
GrossProfit
|
3380000 | |
| us-gaap |
Gross Profit
GrossProfit
|
2294000 | ||
| us-gaap |
Gross Profit
GrossProfit
|
6901000 | ||
| CY2019Q2 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
3272000 | |
| us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
4797000 | ||
| us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
7151000 | ||
| CY2019Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2511000 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5147000 | ||
| CY2019Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1124000 | |
| CY2019Q2 | us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
190000 | |
| CY2020Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
4920000 | |
| CY2019Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
6717000 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
11624000 | ||
| CY2020Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3979000 | |
| CY2019Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3337000 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9330000 | ||
| CY2020Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-40000 | |
| us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-126000 | ||
| us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-48000 | ||
| CY2020Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-625000 | |
| CY2019Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-529000 | |
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-1214000 | ||
| CY2020Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-665000 | |
| CY2019Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-534000 | |
| CY2020Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-4644000 | |
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
121000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
86000 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-1007000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1340000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1055000 | ||
| CY2019Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3871000 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-10670000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-8757000 | ||
| CY2020Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
53000 | |
| CY2019Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
28000 | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
34000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
42000 | ||
| CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4697000 | |
| CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3899000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-10704000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-8799000 | ||
| CY2020Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
74000 | |
| CY2019Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
14000 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
56000 | ||
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-41000 | ||
| CY2020Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-4623000 | |
| CY2019Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-3885000 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10648000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-8840000 | ||
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3792000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
-10704000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-8799000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
488000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
529000 | ||
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
1008000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
74000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
109000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1204000 | ||
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-5000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-3835000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-692000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
37000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9339000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6627000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
81000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
125000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-81000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-125000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3881000 | ||
| biol |
Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
|
3031000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
991000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
38000 | ||
| us-gaap |
Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
|
3140000 | ||
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
2500000 | ||
| us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
3000000 | ||
| us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
3000000 | ||
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
50000 | ||
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
4000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
9011000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2466000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
57000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-38000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-352000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-4324000 | ||
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
6101000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
8356000 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
5749000 | |
| CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4032000 | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
466000 | ||
| us-gaap |
Interest Paid Net
InterestPaidNet
|
831000 | ||
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
26000 | ||
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
12000 | ||
| biol |
Cash Paid For Operating Leases
CashPaidForOperatingLeases
|
188000 | ||
| biol |
Cash Paid For Operating Leases
CashPaidForOperatingLeases
|
414000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
35000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
17000 | ||
| biol |
Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
|
570000 | ||
| biol |
Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
|
824000 | ||
| us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
67000 | ||
| us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
209000 | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.<font style="font-weight:bold;color:#000000;"> </font></p> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers’ financial condition and maintains relationships with the Company’s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of products. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company’s revenue is denominated in U.S. dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company’s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the three and six month periods ended June 30, 2020 and 2019, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S. dollar may affect the price competitiveness of the Company’s products outside the U.S.</p> | ||
| CY2020Q2 | biol |
Expiration Anniversary Date Of Issuance
ExpirationAnniversaryDateOfIssuance
|
P5Y | |
| CY2020Q2 | biol |
Combined Purchase Price Of Shares And Warrants
CombinedPurchasePriceOfSharesAndWarrants
|
0.64 | |
| CY2020Q2 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
6900000 | |
| CY2020Q2 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
800000 | |
| us-gaap |
Proceeds From Other Equity
ProceedsFromOtherEquity
|
6900000 | ||
| CY2020Q2 | biol |
Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
|
0.66 | |
| biol |
Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
|
0.71 | ||
| CY2019Q2 | biol |
Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
|
0.81 | |
| biol |
Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
|
0.82 | ||
| CY2020Q2 | biol |
Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
|
0.34 | |
| biol |
Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
|
0.29 | ||
| CY2019Q2 | biol |
Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
|
0.19 | |
| biol |
Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
|
0.18 | ||
| CY2020Q2 | biol |
Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
|
521000 | |
| CY2019Q4 | biol |
Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
|
559000 | |
| CY2020Q2 | biol |
Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
|
1377000 | |
| CY2019Q4 | biol |
Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
|
2063000 | |
| CY2020Q2 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
1898000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
2622000 | |
| CY2020Q2 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
412000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
385000 | |
| CY2020Q2 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
1486000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
2237000 | |
| biol |
Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
|
400000 | ||
| biol |
Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
|
300000 | ||
| biol |
Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
|
-2000000 | ||
| biol |
Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
|
-400000 | ||
| CY2020Q2 | biol |
Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
|
800000 | |
| CY2019Q2 | biol |
Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
|
500000 | |
| biol |
Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
|
1600000 | ||
| biol |
Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
|
1200000 | ||
| CY2020Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
1400000 | |
| CY2020Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y2M12D | |
| CY2020Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
801000 | |
| CY2019Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
447000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1519000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1204000 | ||
| CY2020Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y6M | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y1M6D | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.031 | |
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.850 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.028 | ||
| CY2019Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y1M6D | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y6M | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.858 | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0036 | |
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0250 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0037 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0260 | ||
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1287000 | |
| biol |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
|
1241000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
108000 | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2420000 | |
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1022000 | |
| biol |
Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod
|
17000 | ||
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.77 | |
| biol |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
|
0.38 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
4.98 | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.04 | |
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
6.45 | |
| biol |
Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
13.2 | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y7M13D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P4Y9M14D | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
108000 | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
3000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1000 | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.29 | |
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.53 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.29 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.53 | ||
| CY2020Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
58000 | |
| CY2019Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
90000 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
134000 | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
431000 | ||
| CY2020Q2 | biol |
Warrant Expiration Period
WarrantExpirationPeriod
|
P5Y | |
| CY2020Q2 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
6900000 | |
| CY2020Q2 | biol |
Combined Purchase Price Per Share And Warrant
CombinedPurchasePricePerShareAndWarrant
|
0.64 | |
| CY2020Q2 | biol |
Other Offering Expenses
OtherOfferingExpenses
|
700000 | |
| CY2020Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
18500000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
18500000 | ||
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5700000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5700000 | ||
| CY2020Q2 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
4013000 | |
| CY2019Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
3689000 | |
| CY2020Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
1166000 | |
| CY2019Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
1064000 | |
| CY2020Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
6753000 | |
| CY2019Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
6242000 | |
| CY2020Q2 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
1300000 | |
| CY2019Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
1300000 | |
| CY2020Q2 | biol |
Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
|
10429000 | |
| CY2019Q4 | biol |
Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
|
10353000 | |
| CY2020Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
9810000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
9322000 | |
| CY2020Q2 | biol |
Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
|
619000 | |
| CY2019Q4 | biol |
Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
|
1031000 | |
| us-gaap |
Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
|
0 | ||
| CY2020Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | ||
| CY2019Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | |
| CY2020Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
300000 | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
500000 | ||
| CY2019Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
300000 | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
500000 | ||
| CY2020Q2 | us-gaap |
Land
Land
|
162000 | |
| CY2019Q4 | us-gaap |
Land
Land
|
162000 | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | ||
| CY2020Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1656000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1726000 | |
| CY2020Q2 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
660000 | |
| CY2019Q4 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
865000 | |
| CY2020Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
218000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
323000 | |
| CY2020Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
415000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
330000 | |
| CY2020Q2 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
19000 | |
| CY2019Q4 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
242000 | |
| CY2019Q4 | us-gaap |
Accrued Insurance Current
AccruedInsuranceCurrent
|
546000 | |
| CY2020Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
581000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
712000 | |
| CY2020Q1 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
1158000 | |
| CY2019Q1 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
1384000 | |
| CY2019Q4 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
1110000 | |
| CY2018Q4 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
1308000 | |
| CY2020Q2 | us-gaap |
Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
|
-261000 | |
| CY2019Q2 | us-gaap |
Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
|
383000 | |
| us-gaap |
Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
|
-18000 | ||
| us-gaap |
Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
|
622000 | ||
| CY2020Q2 | us-gaap |
Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
|
43000 | |
| CY2019Q2 | us-gaap |
Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
|
268000 | |
| us-gaap |
Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
|
238000 | ||
| us-gaap |
Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
|
431000 | ||
| CY2020Q2 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
854000 | |
| CY2019Q2 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
1499000 | |
| CY2019Q2 | us-gaap |
Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
|
735000 | |
| CY2019Q2 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
764000 | |
| CY2020Q2 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
1456000 | |
| CY2019Q4 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
1534000 | |
| CY2020Q2 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
3140000 | |
| CY2020Q2 | us-gaap |
Long Term Debt
LongTermDebt
|
3140000 | |
| CY2020Q2 | biol |
Warrants Adjusted Exercise Price
WarrantsAdjustedExercisePrice
|
0.60 | |
| CY2020Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
2100000 | |
| CY2020Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
5785000 | |
| CY2020Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
10109000 | |
| CY2020Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
|
9000 | |
| CY2020Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
|
137000 | |
| CY2020Q2 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
18140000 | |
| CY2020Q2 | biol |
Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
|
962000 | |
| CY2020Q2 | biol |
Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
|
1828000 | |
| CY2020Q2 | biol |
Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
|
1507000 | |
| CY2020Q2 | biol |
Long Term Debt Maturities Repayments Of Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearFour
|
2460000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P1Y | |
| CY2020Q2 | biol |
Long Term Debt Maturities Repayments Of Interest In Year Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearFive
|
6000 | |
| CY2020Q2 | biol |
Long Term Debt Maturities Repayments Of Interest In Year After Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFive
|
122000 | |
| CY2020Q2 | biol |
Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
|
6885000 | |
| us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | ||
| CY2019Q1 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.1278 | |
| CY2020Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
188000 | |
| CY2020Q2 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
570000 | |
| CY2020Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.123 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
212000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
151000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
154000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
157000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
161000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
835000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
265000 | |
| CY2020Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
570000 | |
| CY2020Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
352000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
152000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
499000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
522000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
533000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
545000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
504000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
2755000 | |
| CY2020Q2 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
0 | |
| CY2019Q2 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
0 | |
| us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
0 | ||
| us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
0 | ||
| CY2020Q2 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.003 | |
| us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.003 | ||
| CY2019Q2 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.005 | |
| us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.003 | ||
| us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 |
